TRILLIUM THERAPEUTICS INC. Research and Development Expense
TRILLIUM THERAPEUTICS INC. reported Research and Development Expense of $9.93 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2021-11-12
- TRILLIUM THERAPEUTICS INC. research and development expense for the quarter ending 2021-09-30 was $9.93M, a 32.76% increase year-over-year.
- TRILLIUM THERAPEUTICS INC. research and development expense for the quarter ending 2021-06-30 was $14.00M, a 95.14% increase year-over-year.
- TRILLIUM THERAPEUTICS INC. research and development expense for the quarter ending 2021-03-31 was $5.92M, a 18.77% increase year-over-year.
- TRILLIUM THERAPEUTICS INC. research and development expense for the quarter ending 2020-12-31 was $5.71M.
- TRILLIUM THERAPEUTICS INC. research and development expense for fiscal 2020 was $25.35M, a 5.02% decline from fiscal 2019.
- TRILLIUM THERAPEUTICS INC. research and development expense for fiscal 2019 was $26.69M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2021-09-30 | $9.93M 10-Q · filed 2021-11-12 | $23.92M derived: sum of 2 quarters · filed 2021-11-12 | $29.85M 10-Q · filed 2021-11-12 | $35.56M derived: sum of 4 quarters · filed 2021-11-12 |
| 2021-06-30 | $14.00M 10-Q · filed 2021-08-13 | $19.92M 10-Q · filed 2021-08-13 | $25.63M derived: sum of 3 quarters · filed 2021-08-13 | $33.11M derived: sum of 4 quarters · filed 2021-11-12 |
| 2021-03-31 | $5.92M 10-Q · filed 2021-05-07 | $11.63M derived: sum of 2 quarters · filed 2021-05-07 | $19.11M derived: sum of 3 quarters · filed 2021-11-12 | $26.28M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-12-31 | $5.71M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $13.19M derived: sum of 2 quarters · filed 2021-11-12 | $20.36M derived: sum of 3 quarters · filed 2021-11-12 | $25.35M 10-K · filed 2021-03-18 |
| 2020-09-30 | $7.48M 10-Q · filed 2021-11-12 | $14.65M derived: sum of 2 quarters · filed 2021-11-12 | $19.64M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $7.17M 10-Q · filed 2021-08-13 | $12.16M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $4.99M 10-Q · filed 2021-05-07 | |||
| 2019-12-31 | $26.69M 10-K · filed 2021-03-18 |